Medicine for treating supraspinatus tendinopathy and preparation method thereof

Abstract

The invention discloses a supraspinatus tendinopathy treatment medicine and a preparation method thereof, and relates to the technical field of tendinopathy medicine preparation. The preparation raw materials comprise 500 g of radix astragali medicinal material and 5 g of cellulase. The specific preparation method comprises the following steps: S1: pretreatment and enzymolysis: S11: selecting and cleaning a radix astragali medicinal material; s12, performing crushing treatment; s13, cellulase treatment: 5 g of cellulase is weighed and pre-activated with warm water for 10 min, and the enzyme activity is increased; and S14, carrying out an enzymatic hydrolysis reaction, namely uniformly spraying the pre-activated cellulase onto the astragalus membranaceus powder. The traditional Chinese medicinal material astragalus membranaceus is adopted, so that the treatment effect of the medicine can be remarkably improved; a method of combining cellulase pretreatment and ethanol reflux extraction is adopted, so that the extraction rate of effective components in the medicinal materials is increased; by optimizing enzymolysis and extraction conditions, such as temperature, pH value, solvent proportion and the like, high purity and high activity of effective components in the extract are ensured.

Description

Technical Field

[0001] The present invention relates to the technical field of preparation of tendinopathy medicines, and in particular to a medicine for treating supraspinatus tendinopathy and a preparation method thereof. Background Art

[0002] Tendinopathy is a common disease that affects tendon function in humans and animals, characterized by tendon pain, swelling, and dysfunction. With the aging of the population and the increase in the number of people exercising, the incidence of tendinopathy has a significant upward trend. Tendinopathy not only brings pain to patients, but also seriously affects their daily life and work efficiency.

[0003] Currently, the treatment of tendinopathy mainly relies on physical therapy and drug therapy, among which drug therapy is mainly based on non-steroidal anti-inflammatory drugs (NSAIDs), but these drugs have problems such as gastrointestinal side effects and poor long-term efficacy.

[0004] After searching, the Chinese patent application number CN202180083992.7 discloses a method and a pharmaceutical composition for treating and preventing microbial infectious diseases and related inflammatory disorders, including a therapeutic agent X or a pharmaceutically acceptable salt thereof; a therapeutic agent Y or a pharmaceutically acceptable salt thereof; and at least one pharmaceutically acceptable excipient, wherein the therapeutic agent X is a nonsteroidal anti-inflammatory drug and the therapeutic agent Y is a fatty acid oxidation inhibitor. The pharmaceutical composition in the above patent has the above-mentioned side effects and efficacy problems. Summary of the invention

[0005] The purpose of the present invention is to solve the shortcomings of the prior art and to propose a drug for treating supraspinatus tendinopathy and a preparation method thereof.

[0006] In order to achieve the above object, the present invention adopts the following technical solutions:

[0007] A method for preparing a drug for treating supraspinatus tendinopathy, wherein the raw materials for the drug include:

[0008] Astragalus: 500g

[0009] Cellulase: 5 g;

[0010] The specific preparation method comprises the following steps:

[0011] S1: Pretreatment and enzymatic hydrolysis:

[0012] S11: Selection and cleaning of Astragalus membranaceus;

[0013] S12: crushing treatment;

[0014] S13: Cellulase treatment: weigh 5 g of cellulase and pre-activate it with warm water for 10 minutes to increase enzyme activity;

[0015] S14: Enzymatic hydrolysis reaction: spray the preactivated cellulase evenly on the astragalus powder, and carry out enzymatic hydrolysis reaction in an environment where the temperature is controlled at 55°C and the pH value is maintained at 4.5-5.0 for 4 hours;

[0016] S15: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is quickly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme;

[0017] S16: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue;

[0018] S2: Ethanol reflux extraction:

[0019] S21: solvent preparation, selecting 85% ethanol as the solvent;

[0020] S22: mixing and refluxing, mixing the enzymatically hydrolyzed astragalus powder with 85% ethanol in proportion, and refluxing for extraction;

[0021] S23: Filtering and merging;

[0022] S24: concentrated powder making;

[0023] S3: separation and purification.

[0024] Preferably: in S1, the selection and cleaning of the astragalus medicinal material specifically comprises: selecting uncontaminated, dry, and mildew-free astragalus medicinal materials, and thoroughly cleaning the astragalus with deionized water to remove surface impurities;

[0025] The crushing process is specifically as follows: the cleaned Astragalus membranaceus medicinal material is placed in a crusher and crushed to a particle size of 60-80 meshes.

[0026] Preferably, in S2, the mixing and refluxing are specifically as follows: the enzymatically hydrolyzed Astragalus powder is mixed with 85% ethanol at a ratio of 1:10 (w / v), placed in a reflux extraction device, heated to boiling ethanol, refluxed for 1 hour, and the process is repeated 3 times.

[0027] Preferably: in S2, filtering and combining specifically include: filtering the extract through filter paper, collecting the filtrate, and combining the filtrates from the three extractions;

[0028] The concentrated powder making process is as follows: the combined extracts are concentrated in a rotary evaporator under vacuum at 40° C. to 1 / 10 of the original volume, and then spray-dried to obtain a crude astragalus flavonoid extract.

[0029] Preferably: S3 specifically includes:

[0030] S31: column chromatography preparation;

[0031] S32: Sample loading: Dissolve the concentrated extract in water and slowly add it to the top of the chromatography column;

[0032] S33: elution and collection;

[0033] S34: Concentration and freeze-drying: The eluate is concentrated again in a rotary evaporator, and freeze-dried to obtain.

[0034] Preferably, in S3, the column chromatography preparation is specifically as follows: polyamide-6 of appropriate particle size is selected as the stationary phase, and filled into the chromatography column, and the column bed volume is 500 ml.

[0035] Preferably, in S3, the elution and collection are specifically as follows: deionized water is used as the mobile phase for elution, the flow rate is controlled at 5 ml / min, the eluent is monitored by a UV detector, and the eluent is collected in sections.

[0036] Preferably: the raw materials for preparing the supraspinatus tendinopathy treatment drug are replaced with:

[0037] Astragalus: 500g

[0038] Salvia miltiorrhiza: 100g

[0039] Cellulase: 6 g;

[0040] The S1 is replaced by the following steps:

[0041] S1: Pretreatment and enzymatic hydrolysis:

[0042] S11: Compound medicinal material processing: Mix the Astragalus membranaceus medicinal material and the Salvia miltiorrhiza extract evenly and then crush them into 60-80 mesh;

[0043] S12: Enzyme preactivation and reaction: After preactivation, the cellulase is evenly sprayed on the mixture, and the enzymatic hydrolysis conditions are adjusted to a temperature of 58°C and a pH value of 4.8, and the enzymatic hydrolysis time is controlled at 5 hours;

[0044] S13: Enzymatic hydrolysis: Ultrasonic wave assisted enzymatic hydrolysis was introduced, and the frequency was set to 35kHz to enhance the contact efficiency between enzyme and medicinal materials;

[0045] S14: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is rapidly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme;

[0046] S15: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue.

[0047] Preferably, the S2 is replaced by the following steps:

[0048] S2: Ethanol reflux extraction:

[0049] S21: Optimize the solvent ratio: adjust the ratio of ethanol to medicinal materials to 1:12 (w / v) to increase the extraction efficiency;

[0050] S22: Multiple reflux extraction: The number of refluxes is controlled at 4 times, and the duration of each extraction is controlled at 1.5 hours;

[0051] S23: Filtration and merging: the extract is filtered through filter paper, the filtrate is collected, and the filtrates of the three extractions are combined;

[0052] S24: Concentration and powder making: The combined extracts are concentrated in a rotary evaporator under vacuum at 40° C. to 1 / 10 of the original volume, and further spray-dried to obtain a crude astragalus flavonoid extract.

[0053] Preferably: the raw materials for preparing the supraspinatus tendinopathy treatment drug are replaced with:

[0054] Astragalus: 500g

[0055] Salvia miltiorrhiza: 100g

[0056] Rhodiola rosea: 60 g

[0057] Cellulase: 7 g;

[0058] The S1 is replaced by the following steps:

[0059] S1: Pretreatment and enzymatic hydrolysis:

[0060] S11: Mixing and crushing of medicinal materials: The three medicinal materials are mixed and crushed together to ensure uniform distribution of the ingredients;

[0061] S12: Enzyme preactivation and reaction: Cellulase was preactivated, the amount of cellulase used was 7 g, the preactivation conditions were adjusted to 40° C., 15 minutes, and after preactivation, the mixture was evenly sprayed, the enzymolysis conditions were adjusted to a temperature of 60° C., a pH value of 5.0, and the enzymolysis time was controlled to 6 hours;

[0062] S13: Enzymolysis: The enzymolysis temperature was adjusted to 60°C, the pH value to 5.0, the time was controlled to 6 hours, and microwave-assisted treatment was introduced to improve the enzymolysis efficiency;

[0063] S14: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is rapidly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme;

[0064] S15: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue.

[0065] The beneficial effects of the present invention are:

[0066] 1. The present invention adopts the traditional Chinese medicinal material Astragalus, which can significantly improve the therapeutic effect of the drug; adopts a method combining cellulase pretreatment and ethanol reflux extraction to improve the extraction rate of effective ingredients in the medicinal material; and optimizes the conditions of enzymatic hydrolysis and extraction, such as temperature, pH value, solvent ratio, etc., to ensure the high purity and high activity of the effective ingredients in the extract.

[0067] 2. Experiments have shown that the drug prepared by the present invention can significantly improve the pathological changes of tendinopathy and promote the repair and regeneration of tendon tissue. Compared with traditional non-steroidal anti-inflammatory drugs, the drug of the present invention is derived from natural herbs, has fewer side effects, and is safer, and is especially suitable for long-term treatment and use by elderly patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] Figure 1 A comparison chart of the therapeutic effects of an experimental drug for treating supraspinatus tendinopathy proposed by the present invention;

[0069] Figure 2 This is a comparative diagram of scx gene expression in an experiment of a therapeutic drug for supraspinatus tendinopathy proposed by the present invention;

[0070] Figure 3 This is a comparative graph of col1 gene expression in an experiment of a therapeutic drug for supraspinatus tendinopathy proposed by the present invention;

[0071] Figure 4 This is a biomechanical comparison diagram of an experiment on a drug for treating supraspinatus tendinopathy proposed in the present invention. DETAILED DESCRIPTION

[0072] The technical solution of the present invention is further described in detail below in conjunction with specific implementation methods.

[0073] Embodiment 1:

[0074] A drug for treating supraspinatus tendinopathy, the raw materials for its preparation comprising:

[0075] Astragalus: 500g

[0076] Cellulase: 5 g;

[0077] The specific preparation method comprises the following steps:

[0078] S1: Pretreatment and enzymatic hydrolysis:

[0079] S11: Selection and cleaning of Astragalus membranaceus;

[0080] S12: crushing treatment;

[0081] S13: Cellulase treatment: Weigh 5 g of cellulase and pre-activate it with warm water (35°C) for 10 minutes to increase enzyme activity;

[0082] S14: Enzymatic hydrolysis reaction: spray the preactivated cellulase evenly on the astragalus powder, and carry out enzymatic hydrolysis reaction in an environment where the temperature is controlled at 55°C and the pH value is maintained at 4.5-5.0 for 4 hours;

[0083] S15: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is quickly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme;

[0084] S16: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue;

[0085] S2: Ethanol reflux extraction:

[0086] S21: solvent preparation, selecting 85% ethanol as the solvent;

[0087] S22: mixing and refluxing, mixing the enzymatically hydrolyzed astragalus powder with 85% ethanol in proportion, and refluxing for extraction;

[0088] S23: Filtering and merging;

[0089] S24: concentrated powder making;

[0090] S3: separation and purification.

[0091] Among them, in S1, the selection and cleaning of the astragalus medicinal material are specifically as follows: selecting uncontaminated, dry, and mildew-free astragalus medicinal materials, and thoroughly cleaning the astragalus with deionized water to remove surface impurities;

[0092] The crushing process is specifically as follows: the cleaned Astragalus membranaceus medicinal material is placed in a crusher and crushed to a particle size of 60-80 meshes to ensure a larger contact area for subsequent reactions.

[0093] Among them, in S2, the mixing and refluxing are specifically as follows: the enzymatically hydrolyzed astragalus powder is mixed with 85% ethanol in a ratio of 1:10 (w / v), placed in a reflux extraction device, heated to boiling ethanol, refluxed for 1 hour, and this process is repeated 3 times.

[0094] Wherein, in S2, filtering and combining specifically include: filtering the extract through filter paper, collecting the filtrate, and combining the filtrates of the three extractions;

[0095] The concentrated powder making process is as follows: the combined extracts are concentrated in a rotary evaporator under vacuum at 40° C. to 1 / 10 of the original volume, and then spray-dried to obtain a crude astragalus flavonoid extract.

[0096] Wherein, the S3 specifically includes:

[0097] S31: column chromatography preparation;

[0098] S32: Sample loading: Dissolve the concentrated extract in water and slowly add it to the top of the chromatography column;

[0099] S33: elution and collection;

[0100] S34: Concentration and freeze-drying: The eluate is concentrated again in a rotary evaporator, and freeze-dried to obtain.

[0101] Among them, in S3, the column chromatography preparation is specifically as follows: polyamide-6 of appropriate particle size is selected as the stationary phase, filled into the chromatography column, and the column bed volume is 500 ml.

[0102] Among them, in S3, the elution and collection are specifically: using deionized water as the mobile phase for elution, the flow rate is controlled at 5 ml / min, the eluent is monitored by a UV detector, and the eluent is collected in sections.

[0103] Embodiment 2:

[0104] A drug for treating supraspinatus tendinopathy. This embodiment is based on Example 1, and its raw materials for preparation include:

[0105] Astragalus: 500g

[0106] Salvia miltiorrhiza: 100g

[0107] Cellulase: 6 g;

[0108] The specific preparation method comprises the following steps:

[0109] S1: Pretreatment and enzymatic hydrolysis:

[0110] S11: Compound medicinal material processing: Mix the Astragalus membranaceus medicinal material and the Salvia miltiorrhiza extract evenly and then crush them into 60-80 mesh;

[0111] S12: Enzyme preactivation and reaction: After preactivation, the cellulase is evenly sprayed on the mixture, and the enzymatic hydrolysis conditions are adjusted to a temperature of 58°C and a pH value of 4.8, and the enzymatic hydrolysis time is controlled at 5 hours;

[0112] S13: Enzymatic hydrolysis: Ultrasonic wave assisted enzymatic hydrolysis was introduced, and the frequency was set to 35kHz to enhance the contact efficiency between enzyme and medicinal materials;

[0113] S14: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is rapidly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme;

[0114] S15: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue;

[0115] S2: Ethanol reflux extraction:

[0116] S21: Optimize the solvent ratio: adjust the ratio of ethanol to medicinal materials to 1:12 (w / v) to increase the extraction efficiency;

[0117] S22: Multiple reflux extraction: The number of refluxes is controlled at 4 times, and the duration of each extraction is controlled at 1.5 hours;

[0118] S23: Filtration and merging: the extract is filtered through filter paper, the filtrate is collected, and the filtrates of the three extractions are combined;

[0119] S24: Concentration and powder making: The combined extracts are concentrated in a rotary evaporator at 40°C in vacuum to 1 / 10 of the original volume, and further spray-dried to obtain a crude astragalus flavonoid extract;

[0120] S3: Isolation and purification:

[0121] S31: Column chromatography preparation: Select polyamide-6 of appropriate particle size as the stationary phase and fill it into the chromatography column with a column bed volume of 500 ml;

[0122] S32: Sample loading: Dissolve the concentrated extract in a small amount of water and slowly add it to the top of the chromatography column;

[0123] S33: elution and collection: deionized water was used as the mobile phase for elution, the flow rate was controlled at 5 ml / min, the eluent was monitored by a UV detector, and the eluent was collected in sections;

[0124] S34: Concentration and freeze-drying: The eluate is concentrated again in a rotary evaporator, and freeze-dried to obtain.

[0125] Embodiment 3:

[0126] A drug for treating supraspinatus tendinopathy. This embodiment is based on Example 2, and its preparation raw materials include:

[0127] Astragalus: 500g

[0128] Salvia miltiorrhiza: 100g

[0129] Rhodiola rosea: 60 g

[0130] Cellulase: 7 g;

[0131] The specific preparation method comprises the following steps:

[0132] S1: Pretreatment and enzymatic hydrolysis:

[0133] S11: Mixing and crushing of medicinal materials: The three medicinal materials are mixed and crushed together to ensure uniform distribution of the ingredients;

[0134] S12: Enzyme preactivation and reaction: Cellulase was preactivated, the amount of cellulase used was 7 g, the preactivation conditions were adjusted to 40° C., 15 minutes, and after preactivation, the mixture was evenly sprayed, the enzymolysis conditions were adjusted to a temperature of 60° C., a pH value of 5.0, and the enzymolysis time was controlled to 6 hours;

[0135] S13: Enzymolysis: The enzymolysis temperature was adjusted to 60°C, the pH value to 5.0, the time was controlled to 6 hours, and microwave-assisted treatment was introduced to improve the enzymolysis efficiency;

[0136] S14: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is rapidly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme;

[0137] S15: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue;

[0138] S2: Ethanol reflux extraction:

[0139] S21: Optimize the solvent ratio: adjust the ratio of ethanol to medicinal materials to 1:12 (w / v) to increase the extraction efficiency;

[0140] S22: Multiple reflux extraction: The number of refluxes is controlled at 4 times, and the duration of each extraction is controlled at 2 hours;

[0141] S23: Filtration and merging: the extract is filtered through filter paper, the filtrate is collected, and the filtrates of the three extractions are combined;

[0142] S24: Concentration and powder making: The combined extracts are concentrated in a rotary evaporator at 40°C in vacuum to 1 / 10 of the original volume, and further spray-dried to obtain a crude astragalus flavonoid extract;

[0143] S3: Isolation and purification:

[0144] S31: Column chromatography preparation: Select polyamide-6 of appropriate particle size as the stationary phase and fill it into the chromatography column with a column bed volume of 500 ml;

[0145] S32: Sample loading: Dissolve the concentrated extract in a small amount of water and slowly add it to the top of the chromatography column;

[0146] S33: elution and collection: deionized water was used as the mobile phase for elution, the flow rate was controlled at 5 ml / min, the eluent was monitored by a UV detector, and the eluent was collected in sections;

[0147] S34: Concentration and freeze-drying: The eluate is concentrated again in a rotary evaporator, and freeze-dried to obtain.

[0148] experiment:

[0149] Using the acromion impingement theory, a microvascular clip was placed under the acromion of mice to construct a tendinopathy model. Four weeks after modeling, significant changes were found in the supraspinatus tendon. HE showed that the collagen fibers of the tendon were disordered and the morphology of the tendon cells was significantly changed (injury group). Clinical treatment was simulated 4 weeks after surgery, and the clip was removed to simulate clinical acromion plasty. Then, flavonoid extracts were given for treatment. After 4 weeks of treatment, it was found that the histological morphology of the supraspinatus tendon was significantly improved (treatment group), the collagen fiber arrangement was improved, and the cell morphology gradually recovered. There was a significant improvement compared with the untreated group; Figure 1 shown.

[0150] The blank control group, the untreated group (8 weeks after modeling), and the treated group (8 weeks after modeling) were collected to extract RNA from the supraspinatus tendon. The qPCR results also showed that the expression of tendon repair-related genes (scx, col1) was significantly increased after treatment, and they were involved in tendon repair; Figure 2 , Figure 3 shown.

[0151] Samples were also collected at different time points for biomechanical testing. The failure load of the blank group was 5.5N, and it was 2.3N after modeling. After 4 weeks, the clamps were removed and observed. The biomechanical results recovered slightly to 2.5N. After the use of flavonoids, the biomechanics was significantly improved. After the clamps were removed, it was 3N. The biomechanical values ​​were significantly improved; Figure 4 shown.

[0152] In general, the extracted drugs significantly improved supraspinatus tendinopathy in mice after treatment from the perspectives of histology, gene expression, and biomechanics, providing a new reference for the clinical treatment of tendinopathy.

[0153] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

Claims

1. A method for preparing a drug for treating supraspinatus tendinopathy, characterized in that: The raw materials for its preparation include: Astragalus: 500g Cellulase: 5 g; The specific preparation method comprises the following steps: S1: Pretreatment and enzymatic hydrolysis: S11: Selection and cleaning of Astragalus membranaceus; S12: crushing treatment; S13: Cellulase treatment: weigh 5 g of cellulase and pre-activate it with warm water for 10 minutes to increase enzyme activity; S14: Enzymatic hydrolysis reaction: spray the preactivated cellulase evenly on the astragalus powder, and carry out enzymatic hydrolysis reaction in an environment where the temperature is controlled at 55°C and the pH value is maintained at 4.5-5.0 for 4 hours; S15: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is quickly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme; S16: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue; S2: Ethanol reflux extraction: S21: solvent preparation, selecting 85% ethanol as the solvent; S22: mixing and refluxing, mixing the enzymatically hydrolyzed astragalus powder with 85% ethanol in proportion, and refluxing for extraction; S23: Filtering and merging; S24: concentrated powder making; S3: separation and purification.

2. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 1, characterized in that: In S1, the selection and cleaning of the astragalus medicinal material specifically include: selecting uncontaminated, dry, and mildew-free astragalus medicinal materials, and thoroughly cleaning the astragalus with deionized water to remove surface impurities; The crushing process is specifically as follows: the cleaned Astragalus membranaceus medicinal material is placed in a crusher and crushed to a particle size of 60-80 meshes.

3. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 2, characterized in that: In S2, the mixing and refluxing are specifically as follows: the enzymatically hydrolyzed Astragalus powder is mixed with 85% ethanol at a ratio of 1:10 (w / v), placed in a reflux extraction device, heated until the ethanol boils, refluxed for 1 hour, and this process is repeated 3 times.

4. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 3, characterized in that: In S2, filtering and combining specifically include: filtering the extract through filter paper, collecting the filtrate, and combining the filtrates of the three extractions; The concentrated powder making process is as follows: the combined extracts are concentrated in a rotary evaporator under vacuum at 40° C. to 1 / 10 of the original volume, and then spray-dried to obtain a crude astragalus flavonoid extract.

5. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 4, characterized in that: The S3 specifically includes: S31: column chromatography preparation; S32: Sample loading: Dissolve the concentrated extract in water and slowly add it to the top of the chromatography column; S33: elution and collection; S34: Concentration and freeze-drying: The eluate is concentrated again in a rotary evaporator, and freeze-dried to obtain.

6. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 5, characterized in that: In S3, the column chromatography preparation is specifically as follows: polyamide-6 is selected as the stationary phase and filled into the chromatography column, and the column bed volume is 500 ml.

7. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 6, characterized in that: In S3, the elution and collection are specifically as follows: deionized water is used as the mobile phase for elution, the flow rate is controlled at 5 ml / min, the eluent is monitored by a UV detector, and the eluent is collected in sections.

8. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 1, characterized in that: The raw materials for preparing the supraspinatus tendinopathy treatment drug are replaced with: Astragalus: 500g Salvia miltiorrhiza: 100g Cellulase: 6 g; The S1 is replaced by the following steps: S1: Pretreatment and enzymatic hydrolysis: S11: Compound medicinal material processing: Mix the Astragalus membranaceus medicinal material and the Salvia miltiorrhiza extract evenly and then crush them into 60-80 mesh; S12: Enzyme preactivation and reaction: After preactivation, the cellulase is evenly sprayed on the mixture, and the enzymatic hydrolysis conditions are adjusted to a temperature of 58°C and a pH value of 4.8, and the enzymatic hydrolysis time is controlled at 5 hours; S13: Enzymatic hydrolysis: Ultrasonic wave assisted enzymatic hydrolysis was introduced, and the frequency was set to 35kHz to enhance the contact efficiency between enzyme and medicinal materials; S14: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is rapidly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme; S15: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue.

9. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 8, characterized in that: The S2 is replaced by the following steps: S2: Ethanol reflux extraction: S21: Optimize the solvent ratio: adjust the ratio of ethanol to medicinal materials to 1:12 (w / v) to increase the extraction efficiency; S22: Multiple reflux extraction: The number of refluxes is controlled at 4 times, and the duration of each extraction is controlled at 1.5 hours; S23: Filtration and merging: the extract is filtered through filter paper, the filtrate is collected, and the filtrates of the three extractions are combined; S24: Concentration and powder making: The combined extracts are concentrated in a rotary evaporator under vacuum at 40° C. to 1 / 10 of the original volume, and further spray-dried to obtain a crude astragalus flavonoid extract.

10. The method for preparing a drug for treating supraspinatus tendinopathy according to claim 9, characterized in that: The raw materials for preparing the supraspinatus tendinopathy treatment drug are replaced with: Astragalus: 500g Salvia miltiorrhiza: 100g Rhodiola rosea: 60 g Cellulase: 7 g; The S1 is replaced by the following steps: S1: Pretreatment and enzymatic hydrolysis: S11: Mixing and crushing of medicinal materials: The three medicinal materials are mixed and crushed together to ensure uniform distribution of the ingredients; S12: Enzyme preactivation and reaction: Cellulase was preactivated, the amount of cellulase used was 7 g, the preactivation conditions were adjusted to 40° C., 15 minutes, and after preactivation, the mixture was evenly sprayed, the enzymolysis conditions were adjusted to a temperature of 60° C., a pH value of 5.0, and the enzymolysis time was controlled to 6 hours; S13: Enzymolysis: The enzymolysis temperature was adjusted to 60°C, the pH value to 5.0, the time was controlled to 6 hours, and microwave-assisted treatment was introduced to improve the enzymolysis efficiency; S14: Termination of enzymatic hydrolysis: After the enzymatic hydrolysis is completed, the temperature is rapidly raised to 70°C and maintained for 10 minutes to terminate the activity of the enzyme; S15: solid-liquid separation: centrifuge at 3000 rpm for 15 minutes, collect the supernatant, and perform secondary extraction on the residue.

Images